EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Psilocybin-Assisted Therapy in Psychiatry: A Narrative Clinical Review of Mechanisms, Therapeutic Applications, and Emerging Evidence (2025–2026)

Teodora Anghel, Adriana Cojocaru iD, Lavinia Hogea iD, Iuliana Costea iD, Amalia Marinca, Raluca Dumache iD, Laura Nussbaum, Iuliana-Anamaria Trăilă iD

Journal of Clinical Medicine · 12.08.2026 · 15 (16) · 6228

DOI: 10.3390/jcm15166228 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 12.08.2026. Verfasst von Teodora Anghel und 7 weiteren Autor:innen. Beteiligte Einrichtung: Neuroscience Department, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Victor Babes University of Medicine and Pharmacy, Timisoara.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Psilocybin-assisted therapy has progressed from early proof-of-concept work to a substantially expanded evidence base, with four pivotal studies published in 2025–2026 that were not incorporated into earlier reviews. This review synthesizes the pharmacological and neurobiological foundations of psilocybin and appraises clinical evidence across major depressive disorder (MDD), treatment-resistant depression (TRD), post-traumatic stress disorder (PTSD), cancer-related distress, and substance use disorders, emphasizing long-term durability, expanding indications, and methodological limitations.

Methods

A narrative review was conducted using a targeted search of PubMed/MEDLINE, Embase, Scopus, and Web of Science (January 2000–April 2026), emphasizing 2025–2026 publications. Predefined eligibility principles prioritized randomized controlled trials, long-term follow-up studies, and systematic reviews; formal PRISMA procedures were not applied, consistent with the narrative design.

Results

Four 2025–2026 studies extend the evidence base: a 52-week follow-up confirming dose-dependent maintenance of antidepressant benefit after a single 25 mg psilocybin session; the first pilot study in Veterans with severe TRD, reporting a 60% response rate at three weeks; the first safety trial in PTSD, where symptom improvement tracked self-transcendent experience intensity but worsened with session anxiety; and a living review of 15 randomized trials confirming a meaningful antidepressant effect while identifying functional unblinding as a substantial threat to effect estimates.

Conclusions

Evidence supports psilocybin-assisted therapy as mechanistically distinct and clinically promising, most strongly in MDD and TRD, with preliminary support in PTSD and Veterans. Functional unblinding, small open-label designs, narrow safety populations, and absent SSRI-integration protocols constrain the current conclusions.

Schlagwörter

Stichwörter der Autor:innen

5-HT2A receptorPTSDaltered statesmajor depressive disordermystical experienceneuroplasticitypsilocybinpsychedelic-assisted therapysubstance use disorderstreatment-resistant depressionveterans

Autor:innen und Institutionen

  • Neuroscience Department, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
  • Neuropsychology and Behavioral Medicine Center, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
  • Psychology Department, West University of Timisoara, 300223 Timisoara, Romania.
  • Center for Studies and Research in Psychology, Faculty of Psychology, "Tibiscus" University, Lascăr Catargiu 4-6, 300559 Timisoara, Romania.
  • Ph.D. School, Faculty of Medicine, Department of Microscopic Morphology, Genetics Discipline, Center of Genomic Medicine, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.

ORCID-Profile: Adriana Cojocaru, Lavinia Hogea, Iuliana Costea, Raluca Dumache, Iuliana-Anamaria Trăilă

Förderung

  • The Victor Babes University of Medicine and Pharmacy, Timisoara

Zitieren

APA

Anghel, T., Cojocaru, A., Hogea, L., Costea, I., Marinca, A., Dumache, R., Nussbaum, L., & Trăilă, I. A. (2026). Psilocybin-Assisted Therapy in Psychiatry: A Narrative Clinical Review of Mechanisms, Therapeutic Applications, and Emerging Evidence (2025–2026). Journal of Clinical Medicine, 15(16), 6228. https://doi.org/10.3390/jcm15166228

Vancouver

Anghel T, Cojocaru A, Hogea L, Costea I, Marinca A, Dumache R, et al. Psilocybin-Assisted Therapy in Psychiatry: A Narrative Clinical Review of Mechanisms, Therapeutic Applications, and Emerging Evidence (2025–2026). Journal of Clinical Medicine. 2026;15(16):6228. doi:10.3390/jcm15166228

BibTeX
@article{Anghel2026,
  author = {Anghel, Teodora and Cojocaru, Adriana and Hogea, Lavinia and Costea, Iuliana and Marinca, Amalia and Dumache, Raluca and Nussbaum, Laura and Trăilă, Iuliana-Anamaria},
  title = {Psilocybin-Assisted Therapy in Psychiatry: A Narrative Clinical Review of Mechanisms, Therapeutic Applications, and Emerging Evidence (2025–2026)},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {16},
  pages = {6228},
  doi = {10.3390/jcm15166228}
}
Kostenlos starten →